$137.82
3.87%
NYSE, Nov 18, 03:59 pm EST. Closed.
ISIN
US58933Y1055
Symbol
MRK

Merck & Co. Stock price

$137.78
-5.85 4.07% 1M
+25.22 22.41% 6M
+32.52 30.89% YTD
+41.35 42.88% 1Y
+35.10 34.18% 3Y
+54.73 65.90% 5Y
+78.79 133.55% 10Y
+95.28 224.20% 20Y
NYSE, Closing price Wed, Nov 18 2026
-5.59 3.90%

AI Insights on Merck & Co. Insights AI Insights on Merck & Co.

How does the company make money?
Who are the company’s main competitors?
What are the key opportunities and risks?
How is the company managed?

Create a Free Account to create an Merck & Co. alert.

Set up alerts on Stock Price, Dividend Yield, Valuation (e.g. P/E or EV/Sales) or Strategy Scores and sit back and relax.

Key metrics

Basic
Market capitalization
$339.7b
Enterprise Value
$383.8b
Net debt
$44.1b
Cash
$9.7b
Shares outstanding
2.5b
Valuation
P/E
142.0
P/S | estimate
5.0 | 5.0
EV/Sales | estimate
5.7 | 5.7
EV/FCF | ex SBC
26.0 | 28.0
P/B
7.6
Dividends
DPS
$3.43
Yield 1Y | 5Y
2.5% | 3.0%
Growth 1Y | 5Y
4.6% | 5.6%
Payout 1Y | 3Y
45.1% | 66.1%
Increased
16 Years
Financials
Revenue | estimate
$67.4b | $67.9b
EBITDA
$17.5b
EBIT
$10.2b
Net Income
$2.5b
Free Cash Flow | ex SBC
$14.7b | $13.7b
Growth
Revenue | estimate
4.9% | 4.5%
EBITDA
-38.3%
EBIT
-57.3%
Net Income
-87.1%
Free Cash Flow
13.0%
Margin
Gross
76.6%
EBITDA
26.0%
EBIT
15.1%
Net
3.6%
Free Cash Flow | ex SBC
21.9% | 20.3%
Financial Health
Equity Ratio
38.4%
Return on Equity
34.7%
ROCE
9.8%
ROIC
4.7%
Debt/Equity
1.2
Share-Based Compensation & Dilution
SBC | % of Revenue
$1.1b | 1.6%
SBC as % of FCF
7.2%
SBC Growth 1Y
31.8%
Share Count Growth 1Y
-0.8%
Shareholder Yield
3.3%
More
EPS
$1.0
FCF per Share
$6.0
Short interest
1.1%
Employees
74k
Rev per Employee
$880.0k

Merck & Co. Stock Analysis

Unlock Scores for Free

Analyst Opinions

35 Analysts have issued a Merck & Co. forecast:

25x Buy
71%
10x Hold
29%

Analyst Opinions

35 Analysts have issued a Merck & Co. forecast:

Buy
71%
Hold
29%

Merck & Co. Events

Past Events
OCT
29
Q3 2026 Earnings Call
21 days ago
OCT
26
Shareholder/Analyst Call - Merck & Co., Inc.
24 days ago
SEP
14
Morgan Stanley 24th Annual Global Healthcare Conference
2 months ago
SEP
9
Wells Fargo 21st Annual Healthcare Conference
2 months ago
AUG
4
Q2 2026 Earnings Call
4 months ago
AUG
3
Special Call - Merck & Co., Inc.
4 months ago
JUN
9
Goldman Sachs 47th Annual Global Healthcare Conference 2026
5 months ago
JUN
4
Jefferies Global Healthcare Conference 2026
6 months ago
JUN
1
Special Call - Merck & Co., Inc.
6 months ago
APR
30
Q1 2026 Earnings Call
7 months ago
MAR
25
Merck & Co., Inc., Terns Pharmaceuticals, Inc. - M&A Call
8 months ago
MAR
3
TD Cowen 46th Annual Health Care Conference
9 months ago
FEB
3
Q4 2025 Earnings Call
10 months ago
JAN
12
44th Annual J.P. Morgan Healthcare Conference
10 months ago
DEC
3
Citi Annual Global Healthcare Conference 2025
12 months ago
DEC
2
Evercore 8th Annual Healthcare Conference
12 months ago
NOV
20
Jefferies London Healthcare Conference 2025
12 months ago
NOV
17
Cidara Therapeutics, Inc., Merck & Co., Inc. - M&A Call
about one year ago
NOV
14
7th Annual Healthcare Symposium
about one year ago
NOV
9
Shareholder/Analyst Call - Merck & Co., Inc.
about one year ago
OCT
30
Q3 2025 Earnings Call
about one year ago

Financial data from Merck & Co.

Sep '26
+/-
%
67,378 67,378
5% 5%
100%
- Direct Costs 15,764 15,764
11% 11%
23%
51,614 51,614
3% 3%
77%
- Selling and Administrative Expenses 11,361 11,361
6% 6%
17%
- Research and Development Expense 30,080 30,080
95% 95%
45%
17,517 17,517
38% 38%
26%
- Depreciation and Amortization 7,344 7,344
61% 61%
11%
EBIT (Operating Income) EBIT 10,173 10,173
57% 57%
15%
Net Profit 2,453 2,453
87% 87%
4%

In millions USD.

Don't miss a Thing! We will send you all news about Merck & Co. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Merck & Co. Stock News

Neutral
Business Wire
●
about 22 hours ago
RAHWAY, N.J.--(BUSINESS WIRE)--Thomas H. Glocer to Retire From Merck Board of Directors in May 2027; Douglas M. Baker, Jr. Appointed Independent Lead Director.
Negative
Reuters
●
one day ago
Merck said on Tuesday it would stop development of its experimental blood cancer drug, nemtabrutinib, after a ​review found the treatment's benefits may not outweigh the ‌risks.
Neutral
Business Wire
●
one day ago
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the discontinuation of the clinical development program evaluating nemtabrutinib (MK-1026), an investigational, oral, non-covalent Bruton's tyrosine kinase (BTK) inhibitor. Nemtabrutinib is being evaluated for patients with chronic lymphocytic leukemia (CLL), sma...
More Merck & Co. News

Company Profile

Merck & Co., Inc. engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock and companion animal species. The Healthcare Services segment offers services and solutions that focus on engagement, health analytics, and clinical services to improve the value of care delivered to patients. The Alliances segment includes results from the company's relationship with AstraZeneca LP related to sales of Nexium and Prilosec. The company was founded in 1891 and is headquartered in Kenilworth, NJ.

Head office United States
CEO Mr. Davis
Employees 74,000
Founded 1891
Website www.merck.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today